TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02878941

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Synovial Fluid Analysis
Description: Synovial fluid aspiration (act of using an 18 gauge needle to obtain synovial fluid from the elbow) in the emergency room for patients with the eligible elbow fracture (as defined in inclusion/exclusion criteria) is performed in conjunction with the anesthetic injection as part of standard of care. The elbow will be prepped as per usual for the anesthetic injection. An 18 gauge needle will be inserted through a lateral approach. The subject's elbow will be aspirated. The syringe with the aspirate would be removed from the needle while the needle would remain in the subject's elbow joint. The syringe with anesthetic would then be connected to the needle, and the anesthetic would be injected into the elbow joint. Therefore, no risks from a separate aspiration would be conferred to the patient.
Study: NCT05107141

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ridge preservation
Description: Ridge preservation in molar areas using a xenograft or an allograft in combination with a barrier collagen membrane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ridge preservation
Description: Ridge preservation in molar areas using a xenograft or an allograft in combination with a barrier collagen membrane

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bone graft plus a collagen membrane

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bone graft plus a collagen membrane
Study: NCT03974932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer Lock Applicator
Description: Applicator for instillation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer Lock Applicator
Description: Applicator for instillation.
Study: NCT01700036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-1-Antitrypsin (AAT)
Description: AAT (Zemaira) will be administered at a dose of 60mg/kg (actual weight) on D1, 4, 8, 12, 16, 20, 24, and 28. A second course of treatment will not be given.
Study: NCT01428050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% NaCl Solution
Description: 1cc/kg/hr of 3%NaCl + 9cc/kg/hr of lactated ringers solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringers Solution
Description: 15cc/kg/hr for intraoperative fluids
Study: NCT03802955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG106
Description: IV infusion over 60 minutes on Day 1 of each cycle, at 7 doses depending on cohort at enrollment.
Study: NCT01176708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dipeptidyl peptidase 4 (DPP4) inhibitor
Description: One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
Study: NCT03974932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: Dual-acting local anesthetic. Dose 2.
Study: NCT01627626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: 0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline.~subjects were instructed to mouthwash with 10ml of solution for 1 minute.
Study: NCT01676558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-rituximab
Study: NCT01873326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT01627626

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 0.9% saline solution
Study: NCT01900522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214 Dose A
Description: ITI-214 Dose A Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214 Dose B
Description: ITI-214 Oral Solution Dose B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214 Dose C
Description: ITI-214 Dose C Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214 Dose D (Elderly)
Description: ITI-214 Dose D (Elderly) Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: ITI-214 Matching Placebo Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214 Dose E
Description: ITI-214 Dose E Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214 Dose F
Description: ITI-214 Dose F Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214 Dose G
Description: ITI-214 Dose G Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214 Dose H
Description: ITI-214 Dose H Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: ITI-214 Matching Placebo Oral Solution
Study: NCT00691457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opti-Free contact lens solution
Description: Solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu Multiplus contact lens solution
Description: Solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care contact lens solution
Description: Solution
Study: NCT01785108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Study: NCT00922246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: custom-made insoles (Thermo+Camel, cost for the military 20,50 euros)
Description: The custom made insoles (Thermo+Camel, cost for the military 20,50 euros) were fabricated from firm-density polyethylene and the hard plastic shell was a three-quarter length.
Study: NCT00334737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa Injection
Description: darbepoetin alfa injection 10 mics/kg once a week SC for 10 weeks or until 35 completed weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erythropoietin alfa injection
Description: Epo 400 units/kg 3 x weekly SC for 10 weeks or until 35 completed weeks gestation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sham injection
Description: sham injection other names: not applicable
Study: NCT01283438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barricaid
Description: Annular closure device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard Limited discectomy
Study: NCT03559517

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ontamalimab
Description: Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ontamalimab
Description: Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
Study: NCT03915990

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: umbilical and middle cerebral artery Doppler
Description: Umbilical and middle cerebral arteries Doppler indices (resistance index and pulsatility index) and Cerebroplacental Doppler ratio will be measured for every patient.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: umbilical and middle cerebral artery Doppler
Description: Umbilical and middle cerebral arteries Doppler indices (resistance index and pulsatility index) and Cerebroplacental Doppler ratio will be measured for every patient.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: umbilical and middle cerebral artery Doppler
Description: Umbilical and middle cerebral arteries Doppler indices (resistance index and pulsatility index) and Cerebroplacental Doppler ratio will be measured for every patient.
Study: NCT04105192

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: dietary supplement consumption
Description: Consumption of the product under study for 84 days, plecebo or experimental product

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary supplement consumption
Description: Consumption of the product under study for 84 days, plecebo or experimental product
Study: NCT04119752

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin powder
Description: 10g of curcumin powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1g of sucralose
Study: NCT04714866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for ADHD
Description: CBT is a time-limited and structured approach that influences change in thoughts, feelings and behavior, leading to symptom changes.
Study: NCT04114916

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apigenin, luteonin, grapefruit extract and citrolive
Description: Two capsules daily at breakfast and dinner.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrina
Description: Two capsules daily at breakfast and dinner.
Study: NCT02018484

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unicompartmental Knee Replacement
Study: NCT01084577

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AQUACEL® Ag
Description: AQUACEL® Ag dressing for four weeks followed by AQUACEL® for the remaining 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urgotul® Silver
Description: Urgotul® Silver for four weeks followed by Urgotul® for the remaining 4 weeks.
Study: NCT01101672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single port laparoscopic colectomy
Description: Patients will be operated by using the technique of single port laparoscopic colectomy by surgeon with experiences and training in this procedure. Laparoscopic instruments will be inserted to perform the procedure through a multi-channel single port which is placed via transumbilical incision. The same transumbilical incision will be extended to 3-4cm for extraction of specimen.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic colectomy
Description: Patient will be operated by techniques of conventional laparoscopic colectomy. A 10mm subumbilical incision is made for camera port, another 2-4 small incisions (5-10mm in size) will be made for placement of ports and insertion of laparoscopic instrument. A 3-4cm abdominal incision will be made for extraction of specimen.
Study: NCT00288015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg IV infusion given on day 1 every 21 days = (1 cycle).
Study: NCT02386462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study: NCT01873326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Study: NCT01602640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine infusion
Description: Conventional dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl and Midazolam infusion
Description: Conventional dose
Study: NCT05374889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open Kinetic Chain Proprioception Exercises
Description: basketball-specific target shooting in open kinetic chain
Study: NCT03898024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1222
Description: Pharmaceutical form: water injection; Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1222
Description: Pharmaceutical form: water injection; Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1222
Description: Pharmaceutical form: water injection; Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1222
Description: Pharmaceutical form: water injection; Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1222
Description: Pharmaceutical form: water injection; Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: water injection; Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: water injection; Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: water injection; Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: water injection; Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: water injection; Route of administration: subcutaneous
Study: NCT04244500

Intervention type: PROCEDURE
Intervention: swab sampling
Description: Multiplex polymerase chain reaction assay for organisms of upper respiratory tract infections
Study: NCT02379819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus Hybrid L24 Implant
Study: NCT02200094

Intervention type: DRUG
Intervention: Low dose of Telmisartan, once daily

Intervention type: DRUG
Intervention: High dose of Telmisartan, once daily
Study: NCT01839331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 mL injection of Ampion
Description: 4 mL Injection of Ampion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 mL Injection of Ampion
Description: 10 mL Injection of Ampion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 4 mL Injection of Placebo
Description: 4 mL Injection of Placebo
Study: NCT01042067

Intervention type: OTHER
Intervention: Blood specimens (whole blood, serum, plasma)
Description: The patients follow standard warfarin treatment regimens and the only intervention is the sampling of blood specimens.
Study: NCT02845986

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Spleen-Preserving No.10 Lymph Node Dissections
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Laparoscopic spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: oxaliplatin or platinum-based chemotherapy is used when the patients undergo adjuvant chemotherapy after the surgery.
Study: NCT00924677

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency neurotomy for genicular nerve
Description: RF cannula was advanced percutaneously towards areas connecting the shaft to epicondyle of femur or tibia. Lidocaine (1 mL of 2%) was injected before activation of the RF generator (NeuroThermTM, Morgan automation LTD, Liss, UK). RF electrode was inserted through RF cannula. The temperature of the electrode tip was raised to 70℃ for 90 seconds by radiofrequency generator.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: radiofrequency neurotomy sham therapy
Description: The placebo (sham) group received the same procedure without activation of the RF generator.
Study: NCT03798639

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Receive radiation therapy
Study: NCT02457650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: On days -7 through -6, Cyclophosphamide 60mg/kg/day IV will be infused over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: On days -5 through -1, Fludarabine 25mg/m2/day IV will be infused over 30 minutes.
Study: NCT01839331

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10 mL Injection of Placebo
Description: 10 mL Injection of Placebo
Study: NCT03649243

Intervention type: DRUG
Intervention: Propolis spray
Description: Propolis was added at the site of injury, 3 puff for any wound in the foot of patients. All the patients decide voluntary if they want to receive the propolis spray treatment or only receive they normal wound healing care.
Study: NCT03224390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: digital family planning screening and referral service
Description: Clients text the service and receive a free call back to complete an automated family planning counseling session that results in a set of recommended methods that fit the client's preferences. The client is matched to family planning providers that offer these methods, and the service sends a referral code that the client can redeem at a facility. When someone receives a referral code, the service tracks them through their encounter with a provider to learn about their experience with the service, the provider, and their choice in contraception. The service also follows-up with clients who do not act on referrals to better understand their reasons and tries different behavioral nudges to promote uptake of contraception. The service does not pay costs the client may incur at a facility.
Study: NCT00703820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: See Detailed Description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: See Detailed Description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: See Detailed Description
Study: NCT01785108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Study: NCT02457650

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-NY ESO-1 TCR-transduced T cells
Description: Modified cells will be infused IV over 30 minutes.
Study: NCT02651324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03598049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: densah burs osseo densification drills
Description: osseo densification of the alveolar bone in maxillary posterior ridge during implant placement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgical burs drilling
Description: conventional implant osteotomy site drilling with implant surgical kit
Study: NCT02986633

Intervention type: OTHER
Intervention: Echocardiography
Study: NCT03310359

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthin
Description: The agent to be tested is astaxanthin, isolated from H. pluvialis following GMP standards. A GRAS notice (GRN000294) was accepted by the Food and Drug Administration (FDA) in January 2010. Agent is stored in capsules at room temperature.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo pill
Study: NCT01898286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DiaPep277®
Description: 1 mg of DiaPep277® subcutaneously in the upper arm at 0, 3, 6, 9, 12, 15, 18, and 21 months, for a total of 8 administrations
Study: NCT01274598

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)
Description: 1x10\^10 CFU by mouth twice daily for 28 days
Study: NCT02081313

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Study: NCT02659813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic archwire
Description: Archwire used to align teeth in an orthodontic fixed brace

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic archwire
Description: Archwire used to align teeth in an orthodontic fixed brace
Study: NCT04899726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rectoscope (P201630551)
Description: Rectoscope (P201630551) allows the identification of the distal section margin in oncological rectal surgery.
Study: NCT00633763

Intervention type: DRUG
Intervention: 18F-fallypride
Description: Single bolus i.v. injection 60 minutes before PET-CT scanning. Maximum activity per single administration 5 mCi; maximum amount of drug per administration \<10 micrograms.

Intervention type: DRUG
Intervention: 18F-fallypride
Description: Single bolus i.v. injection 60 minutes before PET-CT scanning. Maximum activity per single administration 5 mCi; maximum amount of drug per administration \<10 micrograms.

Intervention type: DRUG
Intervention: 18F-fallypride
Description: I.v. bolus maximum activity per single administration 5 mCi; maximum amount of drug per administration \<10 micrograms.

Intervention type: DRUG
Intervention: 18F-fallypride
Description: I.v. bolus maximum activity per single administration 5 mCi; maximum amount of drug per administration \<10 micrograms.
Study: NCT04532125

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-117
Description: Subjects treated with ARGX-117
Study: NCT01785108

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Study: NCT04532125

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects treated with placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-117 + rHuPH20
Description: Subjects treated with ARGX-117 + rHuPH20

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo + rHuPH20
Description: Subjects treated with placebo + rHuPH20

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-117 PH20 SC
Description: Subjects treated with ARGX-117 PH20 SC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PH20 SC
Description: Subjects treated with placebo PH20 SC